TABLE 2.
Baseline Infection Prevalence | |||
---|---|---|---|
Drug CR 76% | Drug CR 38% | ||
Vaccine Cost $30 | |||
Vaccine Efficacy (Prevention) | |||
60% | Combination a | Combination | |
30% | Combination | Combination | |
Vaccine Cost $100 | |||
Vaccine Prevention | |||
60% | $2,655 (4,885 BRL) b, c | Combination | |
30% | $8,807 (16,205 BRL) | $510 (938 BRL) | |
50% Infection Prevalence | |||
Drug CR 76% | Drug CR 38% | ||
Vaccine Cost $30 | |||
Vaccine Efficacy (Prevention) | |||
60% | Combination | Combination | |
30% | $5,532 (10,179 BRL) | Combination | |
Vaccine Cost $100 | |||
Vaccine Efficacy (Prevention) | |||
60% | $9,496 (17,473 BRL) | $1,001 (1,842 BRL) | |
30% | $28,552 (52,536 BRL) | Drug/Combination d |
Combination treatment strategy was economically dominant over all other strategies
Incremental cost-effectiveness ratio (ICER) value of combination treatment compared to no intervention
1 US$ = 1.84 BRL (2010)
While drug treatment dominated the no intervention strategy, combination treatment dominated the strategy involving the vaccine only.